CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2001-08-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.191371898PMID 11526222PMCID PMC58556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells

  2000cited by this paper
• Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process

  2000cited by this paper
• Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma

  2000cited by this paper
• Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

  2000cited by this paper
• CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal.

  2000cited by this paper
• p53: A Potential Target Antigen for Immunotherapy of Cancer

  2000cited by this paper
• CML vaccines as a paradigm of the specific immunotherapy of cancer.

  2000cited by this paper
• Cytokines in cancer therapy.

  2000cited by this paper
• Bystander virus infection prolongs activated T cell survival.

  1999cited by this paper
• In situ T cells in melanoma

  1999cited by this paper
• Accumulation of identical T cells in melanoma and vitiligo-like leukoderma.

  1999cited by this paper
• CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

  1999cited by this paper
• CD4 T Cells and Their Role in Antitumor Immune Responses

  1999cited by this paper
• Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

  1999cited by this paper
• Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

  1999cited by this paper
• High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals

  1999cited by this paper
• In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes.

  1999cited by this paper
• Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

  1999cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions

  1999cited by this paper
• Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo.

  1999cited by this paper
• A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

  1998cited by this paper
• Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

  1998cited by this paper
• T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

  1998cited by this paper
• Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes.

  1998cited by this paper
• Help for cytotoxic-T-cell responses is mediated by CD40 signalling

  1998cited by this paper
• The Central Role of CD4+ T Cells in the Antitumor Immune Response

  1998cited by this paper
• Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies.

  1998cited by this paper
• Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumor.

  1997cited by this paper
• Serological identification of human tumor antigens.

  1997cited by this paper
• Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells.

  1997cited by this paper
• T‐cell‐independent granuloma formation in response to Mycobacterium avium: role of tumour necrosis factor‐α and interferon‐γ

  1997cited by this paper
• Serological analysis of human tumor antigens: molecular definition and implications.

  1997cited by this paper
• Use of adoptive transfer of T‐cell antigen‐receptor‐transgenic T cells for the study of T‐cell activation in vivo

  1997cited by this paper
• Mutant ras epitopes as targets for cancer vaccines.

  1996cited by this paper
• Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.

  1996cited by this paper
• Clinical diagnosis and therapy of cutaneous melanoma in situ

  1996cited by this paper
• T-cell recognition of self peptides as tumor rejection antigens

  1996cited by this paper
• Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

  1996cited by this paper
• Clinical diagnosis and therapy of cutaneous melanoma in situ

  1996cited by this paper
• Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.

  1996cited by this paper
• Medical management of stage IV malignant melanoma. Medical issues

  1995cited by this paper
• Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells

  1995cited by this paper
• Antigen processing in vivo and the elicitation of primary CTL responses.

  1995cited by this paper
• Lipopolysaccharide interferes with the induction of peripheral T cell death.

  1995cited by this paper
• Cationic Liposome-mediated Intravenous Gene Delivery (*)

  1995cited by this paper
• Prevention of anergy induction in cloned T cells by interleukin 12

  1994cited by this paper
• Monoclonal antibodies to murine CD40 define two distinct functional epitopes

  1994cited by this paper
• Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection

  1994cited by this paper
• Tumour progression and the nature of cancer.

  1991cited by this paper
• T-cell subsets in delayed-type hypersensitivity, protection, and granuloma formation in primary and secondary Listeria infection in mice: superior role of Lyt-2+ cells in acquired immunity

  1988cited by this paper

• ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations.

  2024cites this paper
• Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds.

  2024cites this paper
• Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model

  2023cites this paper
• Nanocarriers for cancer nano-immunotherapy

  2022cites this paper
• Avidity in antibody effector functions and biotherapeutic drug design

  2022cites this paper
• The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo

  2021cites this paper
• CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies

  2021cites this paper
• Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity

  2020cites this paper
• Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells

  2020cites this paper
• Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy

  2020cites this paper
• Enterotoxins can support CAR T cells against solid tumors

  2019cites this paper
• Concepts for agonistic targeting of CD40 in immuno-oncology

  2019cites this paper
• Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade

  2019cites this paper
• Understanding how combinatorial targeting of TLRs and TNFR family costimulatory members promote enhanced T cell responses

  2018cites this paper
• Cancer Vaccines

  2017cites this paper
• The Use of Anti-CD40 mAb in Cancer.

  2017cites this paper
• TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

  2017cites this paper
• Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma.

  2016cites this paper
• Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer

  2015cites this paper
• Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors

  2015cites this paper
• Assessment of immunological responses to tumour antigens relevant to the development of therapeutic cancer vaccines

  2015cites this paper
• Role of CD154 in cancer pathogenesis and immunotherapy.

  2015cites this paper
• Impact des inhibiteurs de la voie mTOR sur la réponse immunitaire T anti-tumorale

  2015cites this paper
• Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma

  2015cites this paper
• What Is the Future of Immunotherapy in Ovarian Cancer

  2014cites this paper
• ANTI-TUMOR ACTIVITY OF CPG-ODN IN OVARIAN XENOGRAFT TUMORS

  2014cites this paper
• Targeted Molecular Therapy for Patients with Ovarian Cancer

  2014cites this paper
• Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

  2013cites this paper
• Agonistic CD 40 Antibodies and Cancer Therapy

  2013cites this paper
• Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

  2013cites this paper
• Agonistic CD40 Antibodies and Cancer Therapy

  2013cites this paper
• allogeneic bone marrow chimeras Successful therapy of metastatic cancer using tumor vaccines in mixed

  2013cites this paper
• Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies

  2013cites this paper
• dendritic cells: the Janus face of anti-CD40 Differential effect of agonistic anti-CD40 on human mature and immature

  2013cites this paper
• Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

  2013cites this paper
• Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses

  2012cites this paper
• Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo

  2012cites this paper
• Treatment of Melanoma with Agonist Immune Costimulatory Agents

  2012cites this paper
• Liposome-anchored local delivery of immunomodulatory agents for tumor therapy

  2012cites this paper
• Synergistic CD40 signaling on APCs and CD8 T cells drives efficient CD8 response and memory differentiation

  2012cites this paper
• mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

  2011cites this paper
• Immunotherapy for ovarian cancer: what's next?

  2011cites this paper
• Clinical Immunology of the Dog and Cat

  2011cites this paper
• Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

  2011cites this paper
• Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

  2010cites this paper
• Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

  2010cites this paper
• T Cells Engineered to Express CD40 Ligand + the Tumor Draining Lymph Nodes by CD8 Activation of Tolerogenic Dendritic Cells in

  2010cites this paper
• Poking CD40 for cancer therapy, another example of the Goldilocks effect

  2010cites this paper
• The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

  2010cites this paper
• Activation of tolerogenic dendritic cells in the tumor draining lymph CD8+ T cells engineered to express CD40 ligand

  2010cites this paper
• Activation of Tolerogenic Dendritic Cells in the Tumor Draining Lymph Nodes by CD8+ T Cells Engineered to Express CD40 Ligand

  2010cites this paper
• Molecular mechanism and function of CD40/CD40L engagement in the immune system

  2009cites this paper
• Engraftment Disease and Complete Donor Cell Inhibition of Chronic Graft-versus-Host In Vivo Ligation of CD 40 Results in T Cell Tolerance through + Breaking of CD 8 Byungsuk

  2008cites this paper
• A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response.

  2008cites this paper
• Breaking of CD8+ T Cell Tolerance through In Vivo Ligation of CD40 Results in Inhibition of Chronic Graft-versus-Host Disease and Complete Donor Cell Engraftment1

  2008cites this paper
• Combined Anti-CD40 Conditioning and Well-timed Immunization Prolongs CD8+ T Cell Accumulation and Control of Established Brain Tumors

  2008cites this paper
• CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors

  2008cites this paper
• Age-dependent tolerance to an endogenous tumor-associated antigen.

  2008cites this paper
• Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

  2008cites this paper
• TumorsVirus 40 T Antigen-Induced Pancreatic and Subsequent Immunotherapy of Simian Response to a Highly Tolerogenic Epitope CD8 Anti-CD40 Conditioning Enhances the T

  2007cites this paper
• Anti-CD40 Conditioning Enhances the TCD8 Response to a Highly Tolerogenic Epitope and Subsequent Immunotherapy of Simian Virus 40 T Antigen-Induced Pancreatic Tumors1

  2007cites this paper
• The Antiviral CD8+ T Cell Response Is Differentially Dependent on CD4+ T Cell Help Over the Course of Persistent Infection1

  2007cites this paper
• with Lymphocytic Choriomeningitis VirusInfection Suppresses the Immune Response to Agonistic Anti-CD40 Antibody Profoundly

  2007cites this paper
• Combined TLR/CD40 Stimulation Mediates Potent Cellular Immunity by Regulating Dendritic Cell Expression of CD70 In Vivo1

  2007cites this paper
• This information is current as Dendritic Cell Expression of CD 70 In Vivo Potent Cellular Immunity by Regulating Combined TLR / CD 40 Stimulation Mediates

  2007cites this paper
• Levels of CD40 expression on dendritic cells dictate tumour growth or regression

  2007cites this paper
• Tumor Model Therapeutic Efficacy in an Intradermal Tumor-Specific T Cells but Does Not Mediate Epitope Generates High-Affinity A Modified Tyrosinase-Related Protein 2

  2006cites this paper
• A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model1

  2006cites this paper
• Characterization of RNA in Saliva

  2006cites this paper
• Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: the Janus face of anti-CD40.

  2005cites this paper
• Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation.

  2005cites this paper
• Virus overrides the propensity of human CD40L‐activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN‐γ and Th1 chemokine production

  2005cites this paper
• CD40/CD154 interactions at the interface of tolerance and immunity.

  2004cites this paper
• Therapeutic cancer vaccines.

  2004cites this paper
• Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand

  2004cites this paper
• The role of the CD40 pathway in the pathogenesis and treatment of cancer.

  2004cites this paper
• Identification and functional characterization of novel receptor ligands of CD40 and alpha(v) beta(3) integrin: implications for gene delivery

  2004cites this paper
• IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-211

  2004cites this paper
• Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN

  2004influential citation
• Co-stimulation agonists as a new immunotherapy for autoimmune diseases.

  2003cites this paper
• Distinctive Maturation of In Vitro Versus In Vivo Anti-CD40 mAb-Matured Dendritic Cells in Mice

  2003cites this paper
• Tumor Rejection Phase Antigen Requires CD40 Stimulation during Shared Endogenous Retroviral Tumor Effective Genetic Vaccination with a Widely

  2003influential citation
• Cell Responses + and CD8 CD40 and IL-2: Coordination of Dendritic Administration of Agonistic Antibodies to Synergistic Anti-Tumor Responses After

  2003cites this paper
• In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice1

  2003cites this paper
• Prospects for CD40-directed experimental therapy of human cancer

  2003cites this paper
• Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses 1

  2003cites this paper
• Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase 1

  2003influential citation
• Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.

  2003cites this paper
• In Vivo Ligation of CD 40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD 8 T Cell Effector Function in SV 40 T Antigen Transgenic Mice 1

  2003cites this paper
• A peptide containing a novel FPGN CD40-binding sequence enhances adenoviral infection of murine and human dendritic cells.

  2003cites this paper
• Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends.

  2002cites this paper
• Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis1

  2002cites this paper
• CD40 Ligation in the Presence of Self-Reactive CD8 T Cells Leads to Severe Immunopathology1

  2002cites this paper
• Immunopathology Self-Reactive CD 8 T Cells Leads to Severe CD 40 Ligation in the Presence of

  2002cites this paper
• Amelioration of Experimental Autoimmune Monoclonal Antibody Leads to the Administration of Agonistic Anti-4-1BB

  2002cites this paper
• CD40 stimulation leads to effective therapy of CD40− tumors through induction of strong systemic cytotoxic T lymphocyte immunity

  2002cites this paper
• Uncoupling of Proliferative Potential and Gain of Effector Function by CD8+ T Cells Responding to Self-Antigens

  2002cites this paper
• Adoptive therapy with CD8 + T cells

  2002cites this paper
• Adoptive T-cell therapy for the treatment of solid tumours

  2002influential citation
• Tumour immunology: Manipulating melanoma

  2001cites this paper